Cleared Traditional

K770623 - CONDUCTIVE CREAM-500

K770623 is the FDA 510(k) clearance for CONDUCTIVE CREAM-500 by Graphic Controls Corp.. It is a Class 2 Neurology device (product code GYB) cleared through the Traditional 510(k) pathway after a 4-day FDA review.

K770623 · Graphic Controls Corp. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1977
Decision
4d
Days
Class 2
Risk

K770623 is an FDA 510(k) clearance for the CONDUCTIVE CREAM-500. Classified as Media, Electroconductive (product code GYB), Class II - Special Controls.

Submitted by Graphic Controls Corp. (Mchenry, US). The FDA issued a Cleared decision on April 8, 1977 after a review of 4 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1275 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Graphic Controls Corp. devices

Submission Details

510(k) Number K770623 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 04, 1977
Decision Date April 08, 1977
Days to Decision 4 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
144d faster than avg
Panel avg: 148d · This submission: 4d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GYB Media, Electroconductive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1275
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.